Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tykerb and Radiation in Stage III-IV Head and Neck Cancer
NCT00490061Phase 2Terminated
- Start
- Jul 2007
- Primary completion
- Jan 2013
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2007; status: terminated.
02
Drugs
lapatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00490061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490061.